● Recruiting

Real-World Treatment Study of Koselugo (Selumetinib)

Condition: Neurofibromatosis 1 · Neurofibroma, Plexiform · Sponsor: AstraZeneca

PhaseN/A

Planned participants200

Who can joinAll sexes, 3 Years to 99 Years

Healthy volunteersNo

About this study

As part of a post-approval commitment, the Korean health authority requests a study to characterize safety and effectiveness in patients treated with Koselugo (Selumetinib), an oral selective inhibitor of MAPK kinase (MEK) 1 and 2, by physicians in routine clinical practice settings. This study is designed to assess the known safety profile or identify previously unsuspected adverse reactions and evaluate the effectiveness of Koselugo under conditions of routine daily medical practice in Korea. This study will provide information on the Korean patient population that is treated with the study drug.

This description comes directly from the study's public registry record.

Talk to the study team

AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com

Always discuss trial participation with your own doctor first.

Locations (12)

Research Site	Busan, South Korea	Recruiting
Research Site	Chungcheongbuk-do, South Korea	Recruiting
Research Site	Daejeon, South Korea	Recruiting
Research Site	Gyeonggi-do, South Korea	Recruiting
Research Site	Incheon, South Korea	Recruiting
Research Site	Jeonnam, South Korea	Recruiting
Research Site	Seoul, South Korea	Suspended
Research Site	Seoul, South Korea	Recruiting
Research Site	Seoul, South Korea	Completed
Research Site	Seoul, South Korea	Not Yet Recruiting
Research Site	Wŏnju, South Korea	Recruiting
Research Site	Yangsan, South Korea	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06360406